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Objectives: Pulmonary valve insufficiency remains a leading cause for reoperations in congenital cardiac sur-
gery. The current percutaneous approach is limited by the size of the access vessel and variable right ventricular
outflow tract morphology. This study assesses the feasibility of transapical pulmonary valve replacement based
on a new valved stent construction concept.
Methods: A new valved stent design was implanted off-pump under continuous intracardiac echocardiographic
and fluoroscopic guidance into the native right ventricular outflow tract in 8 pigs (48.5 6.0 kg) through the right
ventricular apex, and device function was studied by using invasive and noninvasive measures.
Results: Procedural success was 100% at the first attempt. Procedural time was 75  15 minutes. All devices
were delivered at the target site with good acute valve function. No valved stents dislodged. No animal had sig-
nificant regurgitation or paravalvular leaking on intracardiac echocardiographic analysis. All animals had a com-
petent tricuspid valve and no signs of right ventricular dysfunction. The planimetric valve orifice was 2.85 0.32
cm2. No damage to the pulmonary artery or structural defect of the valved stents was found at necropsy.
Conclusions: This study confirms the feasibility of direct access valve replacement through the transapical pro-
cedure for replacement of the pulmonary valve, as well as validity of the new valved stent design concept. The
transapical procedure is targeting a broader patient pool, including the very young and the adult patient. The de-
vice design might not be restricted to failing conduits only and could allow for implantation in a larger patient
population, including those with native right ventricular outflow tract configurations.Earn CME credits at
http://cme.ctsnetjournals.org
Reoperative pulmonary valve replacement becomes neces-
sary in 2 situations: (1) pulmonary valve regurgitation, gen-
erally after surgical transannular patch repair in patients with
tetralogy of Fallot,1-3 and (2) dysfunction of the biologic
valved conduit, establishing the continuity between the right
ventricle and the pulmonary artery.4 Current practice con-
sists of surgical pulmonary valve replacement or replace-
ment of the failing conduit, respectively.
Several alternative strategies, particularly in the presence
of dysfunction of the biologic valved conduit, have been
considered within the last years, including new biologic
valved conduits5-7 and endovascular procedures to delay
the surgical replacement of the obstructed conduit8-12 and
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Endovascular stenting of stenosed right ventricular con-
duits is limited by the resulting pulmonary regurgitation
and the subsequent right ventricular volume overload, re-
sulting in increased incidence of sudden death, ventricular
arrhythmias, and ventricular dysfunction.8,9
There is no doubt about the many advantages of valved
stent implantation for both stenotic and dilated conduits.
The currently used pulmonary valved stent device presents
two limitations. The first relates to the maximum valve
diameter of 22 mm resulting from the particular origin and
processing of the harvested bovine jugular vein. The second
particularity is that the device stent geometry only allows
implantation in a small percentage of patients (13%)
because of the variable morphology of the aneurismal
conduits.13,14
A further challenging limitation is the size mismatch be-
tween the venous access vessel and the introducer size. The
18F introducer allows implantation only in older children.15
This study addresses the mentioned shortcomings by
focusing on approaching the failing conduit by means of
a direct access valve replacement strategy through the right
ventricular apex in the so-called transapical procedure. A
new device allowing perprocedural construction was de-
signed and tested in vivo. Furthermore, the proposed valved
stent concept was validated by random participants at 2 con-
secutive medical technology events in Switzerland.16
MATERIALS AND METHODS
Based on our previous experience with pulmonary valved stents, a
second-generation device allowing so-called periprocedural construction,gery c April 2009
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ICE ¼ intracardiac echo
IVUS ¼ intravascular ultrasound
RVOT ¼ right ventricular outflow tract
meaning building the device during the procedure instead of before, was
implanted in 8 pigs (48.5 6.0 kg). Performing direct access valve replace-
ment via the transapical procedure through a subxiphoid incision permitted
for off-pump implantation.
Valved Stent and Delivery Device Construction
The valved stent is built from 2 components: a valved bovine jugular
vein conduit (Contegra pulmonary valved conduit; Medtronic International
Trading SARL, Tolochenaz, Switzerland) and a size-matched endopros-
thetic graft (Valiant thoracic stent graft, Medtronic; Figure 1). The scaffold
is constructed by shortening the endoprosthetic graft down to 2 segment
lengths, including 2 rows of Z stents. The valved conduit is then cut to ap-
proximate the stent graft length. The trimmed valve conduit is introduced
into the stent graft, and 2 suture lines are started at each end to safely secure
the 2-layer composite device.
The delivery device consists of a large 25F endograft delivery system
(XCelerant, Medtronic; Figure 2) to accommodate for the manually crimped
and loaded valved stent. Delivery is performed by means of counterclock-
wise turning of the rotational handle or by using a quick-release mechanism,
resulting in a pullback motion of the delivery sheath. A more detailed de-
scription of the device assembly has been reported previously.16
All devices (Figure 1) underwent in vitro testing before experimental in
vivo implantation. Static leakage testing and dynamic pulsatile mock-loop
assessment were performed. Real-time intravascular ultrasonography (12.5
MHz, 6F; Clearview; Boston Scientific Corp, Sunnyvale, Calif) was used to
assess the correct functioning of the valved stent over an observation period
of 30 minutes. Both tests have been described previously.17
Surgical Access
For tracheal intubation and mechanical ventilation, general anesthesia
was induced with 22 mg/kg ketamine, 0.8 mg/kg atropine administered in-
tramuscularly, and 15 mg/kg thiopental administered intravenously and
maintained with 2.5% isoflurane. Continuous monitoring of electrocardio-
graphic results, arterial pressure (from a catheter in the right carotid ar-
tery), central venous pressure, and oxygen saturation was performed.
Additional intravenous access was gained through the superficial vein of
the left ear.
After bilateral preparation of the carotid arteries and the jugular veins,
a Swan–Ganz catheter for continuous cardiac output measurements was
temporarily inserted through the right jugular vein, and a second intrave-
nous line was placed in the left jugular vein. Then the arterial pressure
line was inserted into the left carotid artery. Access for the intracardiac echo-
cardiogram was obtained by exposing the proximal right femoral vein and
inserting an 11F introducer (B-Braun; Medical, Inc, Bethlehem, Pa).
Next, the endoscope was introduced into the right lower hemithorax to
identify the preferred primary access for device insertion. Frequently, the
location was subxiphoid to paraxiphoid. Then a 2- to 4-cm incision was
performed. A xylocain (1.5 mg/kg) drip was started to minimize arrhyth-
mias before mobilization of the pericardium. Two Teflon felt–reinforced
Prolene (4–0) orthogonal U stitches were placed on the right ventricular
apex. After heparinization (300 IU/kg), the 10F intracardiac echo (ICE)
probe with the bidirectional steering tip (Sequoia; operating frequencies,
4.0–10.0 MHz; 90-cm insertion length; Acuson Corp, Mountain View,
Calif) was inserted to visualize the delivery process, as well as to measure
the right ventricular outflow tract (RVOT) dimensions and the nativeThe Journal of Thoracic and Cpulmonary valve, including annular diameter, valvular surface, and mor-
phology of the pulmonary root.
Off-Pump Pulmonary Valved Stent Implantation
The valved stent was hand crimped onto the delivery system (Figure 2).
Next, the prepared right ventricular apex was punctured, and an over-the-
needle 8F introducer system (Arrows, Reading, Pa) was inserted. Under
fluoroscopic guidance, a soft-tip 0.035-inch guide wire was first advanced
into the right pulmonary artery and then transcatheter exchanged for an
ultrastiff Back-up Meier wire (0.035 inches, 185 cm; Boston Scientific,
Medi-tech,Watertown,Mass; Figure 3). Then themonorail wire-guided dis-
posable intravascular ultrasound (IVUS) 6F catheter transducer (Sonicath
Ultra 6, 12.5-MHz Imaging Catheter; Medi-tech) providing a cross-sec-
tional view with 80 mm of diameter was inserted. Simultaneous tracking
of the IVUS probe with fluoroscopy allowed for identification and marking
of the desired landing zone. Two radio-opaque markers were placed on
the body surface18,19 to temporarily define the target zone, one at the
FIGURE 1. Late stage of the construction process is displayed (upper left
corner). The finalized device displaying the Contegra valve placed in the
Valiant endograft segment is shown. The front view of the device is shown
in the right lower corner.
FIGURE 2. The valved stent manually crimped and partially loaded into
the 25F Valiant delivery system.ardiovascular Surgery c Volume 137, Number 4 915
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DFIGURE 3. Four views of the implantation procedure (from top left to bottom right): device loaded onto the delivery system; endoscopic assessment of the
ideal transapical procedure access location; 2- to 4-cm paraxiphoid or subxiphoid incision; insertion of the delivery system tip into the right ventricular apex.fluoroscopic level of the pulmonary annulus and the second at the level of
the pulmonary bifurcation.
Periprocedural Valved Stent Position Assessment
With ICE and Fluoroscopy
The IVUS probe and the 8F introducer were removed. The loaded and
flushed valved stent delivery systemwas inserted over the guide wire during
fluoroscopic and simultaneous ICE guidance. After the fluoroscopic and ul-
trasonographic target sites were congruent, the valved stent was deployed
orthotopically over the native valves in a 2-step procedure. First the distal
end and then, if the location stayed unchanged, the proximal end was re-
leased. The valved stent’s initial landing site was chosen slightly above
the prior identified target site to accommodate for minor position correc-
tions. Therefore after opening the first row of Z stents, the whole device
could be pulled back until the landing and target site matched the fluoro-
scopic and ultrasonographic assessments. No contrast medium was used
throughout the procedure.
Outcome Assessment
After device deployment, the 6F IVUS transducer was reintroduced
through the valve. Further measures were taken with the Doppler-support-
ing 8F ICE probe positioned in the right atrium. Finally, a 5F catheter
(Cook, Inc, Bloomington, Ind) was inserted over the guide wire to assess
the transvalvular gradient, the 7.5F Swan-Ganz catheter was advanced
into the pulmonary artery, and cardiac output was measured. The observa-
tion period was 6 hours.
Acute in vivo assessment included the length and diameter of the pulmo-
nary trunk before implantation, device position, leaflet motion, planimetric
valve orifice, transvalvular gradient, regurgitation, and paravalvular leak-
ing. At the end of the experiments, the animals were killed, andmacroscopic
analysis was performed at necropsy.
The institutional Committee on Animal Research approved the protocol.
All animals received human care in compliance with the ‘‘Principles of lab-
oratory animals’’ formulated by the National Society of Medical Research
and the ‘‘Guide for the care and use of laboratory animals’’ prepared by
the Institute of Laboratory Animal Resources and published by the National916 The Journal of Thoracic and Cardiovascular SurInstitutes of Health (National Institutes of Health publication no. 85–23,
revised 1985). All data are expressed as the mean  standard deviation.
RESULTS
Procedural success was 100% (8/8 pigs) at the first at-
tempt. Mean procedure time, including device construction,
was 75 15 minutes. All valved stents were delivered at the
target site over the native pulmonary valve with good acute
valve function. No valved stents dislodged into either the
right ventricle or the pulmonary trunk.
No significant hemodynamic differences between mean
carotid arterial pressure, oxygen saturation, or central ve-
nous pressure before and after implantation were identified
(P1 ¼ .45, P2 ¼ .57, and P3 ¼ .64) during implantation; in
2 cases temporary supraventricular tachycardia was experi-
enced. Continuous cardiac output remained stable through-
out the procedure at 4.20  1.35 L/min.
The peak-to-peak transvalvular pressure gradient ranged
from 5.7 3.1 mm Hg (range, 4.2–10.4 mm Hg) at Doppler
echocardiographic analysis and 4.9  2.4 mm Hg (range,
1–7 mm Hg) on invasive measurements.
The native pulmonary artery diameter at the valve level
was 19.4  1.6mm (approximately 2.9 cm2).
The length of the pulmonary trunk measured 4.2  0.4
cm. No animal had significant regurgitation or paravalvular
leak after implantation on intracardiac echocardiographic
analysis. The IVUS demonstrated the complete opening
and closing of the valve, with a planimetric valve orifice
of 2.85  0.32 cm2.
No damage to the pulmonary artery or structural defects of
the valved stents was found at necropsy. Macroscopic analysisgery c April 2009
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zone. Neither thrombus formation nor leaflet damage or struc-
tural device failurewere identified on gross visual examination.
DISCUSSION
Transcatheter pulmonary valve replacement harbors
many benefits, even more so in the setting of reoperation
for dilated conduits or progressive pulmonary incompetence
after a nonvalved RVOT enlargement strategy. The purpose
of the valve replacement is to restore physiologic hemody-
namic conditions and to prevent or reduce the incidence of
sudden death, arrhythmias, and right ventricular dysfunc-
tion1,2,20 with the lowest possible surgical risk.
Reoperations become necessary in at least 10% of all pa-
tients after primary correction of tetralogy of Fallot. Indica-
tions typically are RVOT enlargement and progressive
pulmonary regurgitation after patch repair.3 Perioperative
and postoperative mortality of surgical pulmonary valve re-
placement is close to zero.2 Postoperative results are excel-
lent, with marked clinical improvements due to right
ventricular end-diastolic volume regression.
Transvenous remote insertion for percutaneous pulmonary
valve replacement remains restricted to a small percentage13 of
patients. The Melody transcatheter pulmonary valve (Med-
tronic B.V., Heerlen, The Netherlands) is limited 2-fold, first
by a very defined morphology of the failing right ventricular
conduit and second by the size of the access vessel, allowing
insertion of the 18F delivery system only in larger femoral
veins or children weighing more than 25 kg, respectively.
Our experimental study presents an alternative off-pump
approach. Direct access valve replacement through the trans-
apical procedure through the right ventricular apex allows
for ‘‘larger’’ device implantation, regardless of the patient’s
age and vascular tree, allowing implantation also in adult
patients.3 Increased device dimensions rationalize implan-
tation also in patients with worsening dilatation of the
RVOT after previous patch enlargement. In a previous
porcine study with heavier adult animals, the mean external
device diameter was measured at 26.3  0.7 mm.21
The present study focused on reproducing conditions of
a pediatric patient population. Because the device is self-ex-
panding, it might be able to adapt to the growing pulmonary
artery, and further device dilatation might be supplemented
by balloon dilatation. Furthermore, the device design might
make it more suitable for native RVOT implantation.
Valved stent device construction is believed to be simple
and safe enough when handled by trained and experienced
personnel. The perprocedural patient-adapted construction
concept was further validated in 2 consecutive medical tech-
nology meetings with more than 70 random participants and
a 92% successful device construction and implantation.16
Biotolerance, functionality, and approval of both compo-
nents are expected to face no major resistance because the
bovine jugular vein conduit, as well as the endograft, are ap-The Journal of Thoracic and Cproved for clinical use, the first for RVOT reconstruction in
congenital patients with failing conduits and the second in
endoluminal grafting of aortic aneurysm. Diverse studies
have shown good midterm outcomes of the bovine jugular
graft in well-selected patients.22-25 The valve has also shown
its validity in percutaneous procedures in more than 300 pa-
tients within the commercially available Melody device
(Bonhoeffer P, personal communication). Nevertheless,
long-term results will remain a matter of debate until further
studies are performed. Durability of the valve might be al-
tered by the implantation within the prosthetic graft, but
only chronic and future clinical implants can clarify those
concerns. The valvular device component might be changed
to a commercial stentless tissue valve or to a homograft im-
planted into the self-expanding endograft to accommodate
larger native RVOTs, but again, follow-up animal studies
will have to show the validity of the modified device.
A similar device, the Shelhigh injectable pulmonic valve
(Shelhigh, Inc, Union, NJ),26 showed very promising re-
sults27,28 and confirmed the clinical feasibility of intraoper-
ative implantation for pulmonary regurgitation. Six patients
(9–27 years of age) with primary total correction of tetralogy
of Fallot at 4.2  4.0 years of age received the injectable
porcine pulmonary valved stent. No major adverse event
was reported, and all except one implantation was success-
ful, with encouraging 6- to 12-month follow-up data.
The former device required additional fixation by using
a few surgical stitches. In the present study we did not expe-
rience either dislodgement or migration, but of course this
very justified concern remains a key element for successful
outcomes. This complication might be prevented by using
a carrier graft with enforced anchoring capacity, such as
hooks or barbs, to help improve anchoring in native, dilated,
or noncalcified RVOTs. This represents a new device con-
cept the authors are currently investigating.
The presented preliminary experimental data are limited to
acute experimental observations but doharbor essential condi-
tions for clinical implementation in the near future. Of course,
the concept requires further validation in chronic studies.
CONCLUSIONS
The off-bypass transapical implantation of a self-expanding
valved stent is feasible over the native pulmonary valve. Intra-
vascular and intracardiac echocardiography combined with
fluoroscopy makes implantation and evaluation easy and re-
producible; there is no need for angiography. The off-bypass
transapical approach allows for valved stent implantation of
any size, including the adult size,with adequate hemodynamic
functioning regardless of the size of the access vessel.
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